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Background: Mucocutaneous blistering is characteristic of autoimmune bullous dermatoses (AIBD). Blisters are
caused by autoantibodies directed against structural components of the skin. Hence, detection of specific autoantibodies
has become a hallmark for AIBD diagnosis. Studies on prevalence of AIBD autoantibodies in healthy individuals yielded
contradictory results.
Methods: To clarify this, samples from 7063 blood donors were tested for presence of anti-BP180-NC16A, anti-BP230
and anti-Dsg1/3 IgG by indirect immunofluorescence (IF) microscopy using a biochip.
Results: Cumulative prevalence of these autoantibodies was 0.9 % (CI: 0.7–1.1 %), with anti-BP180-NC16A IgG being
most prevalent. Validation of IF findings using ELISA confirmed presence of autoantibodies in 7/15 (anti-Dsg1), 6/7
(anti-Dsg3), 35/37 (anti-BP180-NC16A) and 2/3 (anti-BP230) cases. Moreover, in 16 samples, anti-BP180-NC16A
autoantibody concentrations exceeded the cut-off for the diagnosis of bullous pemphigoid. Interestingly, these
anti-BP180-NC16A autoantibodies from healthy individuals formed immune complexes with recombinant antigen
and dose-dependently activated neutrophils in vitro. However, fine-epitope mapping within NC16A showed a
different binding pattern of anti-BP180-NC16A autoantibodies from healthy individuals compared to bullous
pemphigoid patients, while IgG subclasses were identical.
Conclusions: Collectively, we here report a low prevalence of AIBD autoantibodies in a large cohort of healthy
individuals. Furthermore, functional analysis shows differences between autoantibodies from healthy donors and
AIBD patients.
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Autoimmune bullous dermatoses (AIBD) are clinically
characterized by chronic mucocutaneous blistering, lead-
ing to severe morbidity and increased mortality [1–4].
Blister formation is directly or indirectly caused by auto-
antibodies binding to structural proteins of the skin [5, 6].
Depending on the location of the blister and the targeted
autoantigens, AIBD can be classified as pemphigus and
pemphigoid disease, epidermolysis bullosa acquisita (EBA)
and dermatitis herpetiformis [7, 8]. Epidemiological studies* Correspondence: hiroshi_koga@med.kurume-u.ac.jp
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unless otherwise stated.have documented the incidence of AIBD in several geo-
graphic regions. In central Europe, bullous pemphigoid
(BP) had the highest incidence, with 6.1 to 42.8 cases per
million persons per year [1, 3, 4, 9–13]. For pemphigus
disease, including pemphigus vulgaris (PV) and pemphigus
foliaceus (PF), the reported incidence ranged from 0.6 to
6.8 cases per million persons per year [1, 14–16].
For other autoimmune diseases, studies analyzed
serum samples obtained from individuals before they
received a diagnosis of systemic lupus erythematousus
(SLE) or rheumatoid arthritis (RA). These studies clearly
demonstrated the presence of autoantibodies several
years before diagnosis [17, 18]. Derived from these find-
ings, one may assume that autoantibodies in AIBD also
predate the onset of the corresponding disease. However,tral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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0.005 %, to conduct such an investigation with 50–100
AIBD patients would require a predated serum collec-
tion of 1–2 million people. In addition, clinically healthy
individuals have not been systematically investigated for
the presence of autoantibodies to structural proteins of
the skin and the reported autoantibody prevalence is
contradictory. For example, the following autoantibody
prevalence rates in healthy populations have been reported:
0–0.7 % for autoantibodies to desmoglein 1 (Dsg) (PF auto-
antigen); 0–0.2 % for anti-Dsg3 (PV autoantigen); 0-2 % for
anti-BP180-NC16A (BP autoantigen); and 0-7 % for anti-
BP230 (BP autoantigen) antibodies (Table 1). Therefore, in
this study, we aimed at determining the prevalence of
autoantibodies against desmosomal and hemidesmosomal
structural proteins in a large population of healthy blood
donors. In addition, the potential pathogenic relevance of
the detected autoantibodies was evaluated.
Methods
Blood Donors
This study included 7063 normal blood donors from the
Institutes for Transfusion Medicine Lübeck, Kiel and
Frankfurt between August 2010 and March 2011. All
samples were anonymized immediately after blood draw-
ing to comply with requirements by the ethics commit-
tees. To avoid duplicate testing of the same person,
blood samples from all frequent donors were collected
within eight weeks, which is the shortest possible donation
interval for men. Further collection was restricted to first-
time donors. All plasma aliquots were stored at −20 °C
until further testing. All participants signed an informed
consent. The study was performed according to the prin-
ciples of the Declaration of Helsinki and was approved by
the local ethics committees (10–094, the ethics committee
of the University of Lübeck).Table 1 Previously reported prevalence rates of autoantibodies
to structural proteins of the skin
Antigen Population (n) Prevalence Reference
Dsg1 Normal subjects (53) 0.0 % [35]
Blood donors (401) 0.7 % [20]
Dsg3 Normal subjects (53) 0.0 % [35]
Blood donors (401) 0.2 % [20]
BP180* Healthy volunteers (47) 0.0 % [36]
Blood donors (494) 2.0 % [19]
Normal subjects (336) 1.5 % [37]
Healthy subjects (61) 0.0 % [38]
BP230 Normal controls (109) 0.0 % [39]
Healthy controls (56) 7.0 % [40]
Blood donors (483) 2.1 % [41]
*to BP180-NC16A if not otherwise notedAutoantibody screening
Plasma samples from all 7063 donors were analyzed for
the presence of pemphigus- and pemphigoid-related
antibodies with a commercial indirect immunofluores-
cence (IF) assay (dermatology-mosaic 7, EUROIMMUN
AG, Lübeck, Germany) at a 1:10 dilution. The assay
included the following substrates: primate esophagus,
primate salt split skin, recombinant tetrameric BP180-
NC16A and transfected HEK293 cells that express re-
combinant BP230, Dsg1 or Dsg3. Specific fluorescence
(Additional file 1) at a dilution of 1:10 was considered
positive, as advised in the instruction manual. Indirect
IF microscopy-positive samples were subsequently evalu-
ated for specific antibodies (IgG) with enzyme-linked im-
munosorbent assays (ELISA, Anti-BP180-NC16A-ELISA,
Anti-BP230-CF-ELISA, Anti-Dsg-1-ELISA, Anti-Dsg3-ELISA,
all EUROIMMUN AG) [19, 20]. These different ELISAs
share a detection threshold of 0.5 to 0.6 RU/ml and lin-
earity from at least 10 to 199 RU/ml. Calibrators with
2, 20 and 200 RU/ml were used to quantify the measured
extinction rates with computer software. For values below
1 RU/ml, the software is technically unable to calculate
exact values, so that values for these samples are set “<1
RU/ml” and were considered negative. To consolidate the
read out from indirect IF microscopy, a comparable num-
ber of indirect IF microscopy-negative samples were also
tested for each of the relevant antigens by ELISA.ROS release from human PMN
ROS release from immune complex-activated human
PMN was performed as described in [21] with some
modifications. Briefly, 500 ng of tetrameric form of the
NC16A domain of BP180 recombinant protein [19] was
coated each wells followed by addition of 1:10 diluted
plasma samples and incubation for 1 h. After washing
well, PMN was added to each well. Each sample was
tested with PMNs isolated from 3 healthy donors in
duplicate.Determination of IgG subclasses
For determination of BP180-NC16A IgG1-4 reactivity, a
commercial BP180-NC16A ELISA was used [19] and
adapted to detect IgG1-4 antibodies. After incubation
with human plasma, ELISA plates were incubated with
biotin-conjugated mouse anti-human IgG1, IgG2, IgG3
and IgG4 antibodies (Invitrogen, Camarillo, CA), followed
by incubation with peroxidase-conjugated donkey anti-
mouse IgG antibody (minimal cross-reaction to serum
proteins of other species, Jackson ImmunoResearch La-
boratories, West Grove, PA). As we found low BP180-
NC16A-IgG4 reactivity, the sensitivity of the protocol was
evaluated using sera from pemphigus patients. Here, we
frequently detected anti-Dsg3 IgG4 autoantibodies (not
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value +3SD from 10 healthy blood donors.
Fine epitope mapping of anti-BP180-NC16A reactivity
For determination of the reactivity of BP180-NC16A+ sera
to BP180-NC16A2-3 (Biotin-RSILPYGDSMDRIEKDRLQG
MAPAAGADL, Peptides and elephants GmbH, Potsdam,
Germany), we followed previously described protocols [22].
Briefly, streptavidin-coupled microtiter plates were coated
for 1 h on a shaker with 200 ng of the biotinylated synthetic
peptide. After washing the plate, sera diluted 1:200 in PBST
were added to the plate and incubated for 1 h, followed by
HRP-conjugated anti-human IgG incubation for 1 h. Bound
IgG were visualized by 1-Step Turbo TMB-ELISA (Pierce,
Rockford, IL) and measured at 450 nm. The cut-off value
was determined as mean value +3SD from 10 healthy blood
donors. Each sample was tested in duplicate.
Dsg3 internalization assay
HaCaT cells were cultured with keratinocyte growth
medium 2 (PromoCell GmbH, Heidelberg, Germany). At
confluence, the calcium concentration of the medium
was adjusted to 1.5 mM and incubated for 24 h. Then,
1 mg/ml of IgG purified from healthy donors (Intratect®,
Biotest Pharma GmbH, Dreieich, Germany), PV patients
or healthy donors with or without anti-Dsg3 antibodies
at dilution indicated at the Figure legends was added to
HaCaT cells and incubated at 37 °C in a CO2 incubator
for 24 h. After incubation, the cells were fixed and
permeabilized followed by blocking with 1 % BSA and
10 % normal goat serum. Dsg3 was detected by mouse
anti-Dsg3 antibody (Acris antibodies, Herford, Germany)
and Cy3-goat anti-mouse IgG (Jackson ImmunoResearch,
West Grove, PA). Fluorescence images were obtained
using a fluorescence microscope (BZ-9000, Keyence,
Osaka, Japan). To determine the anti-Dsg3 antibody
index value, all samples were adjusted 15 mg/ml and
measured by anti-Dsg3-ELISA (EUROIMMUN AG).
Statistical analysis
Statistical analysis was performed with Gnu R (version
2.14.1, http://www.r-project.org) together with package
“epitools” (version 0.5–6) for calculation of Wilson con-
fidence intervals for binomial counts. ELISA values of
IIF-positive and IIF-negative samples were compared by
the Wilcoxon rank-sum test with continuity correction
using SigmaPlot (Version 12).
Results
Low prevalence of pemphigus and pemphigoid
autoantibodies in the general population
For this study, plasma samples from 7063 healthy blood
donors were collected and tested for reactivity with
autoantigens in AIBD using indirect IF microscopy withantigens coated on a biochip. Autoantibody reactivity in
positively rated samples was validated using commer-
cially available ELISA systems. From these 7063 samples,
a total of 62 samples reacted with at least one of the
recombinant substrates used for indirect IF microscopy,
amounting to a 0.88 % (95 % CI: 0.66–1.10 %) overall
prevalence of autoantibodies to desmosomal and/or
hemidesmosomal structural proteins of the skin. Of
these, 0.52 % (95 % CI: 0.36-0.69 %) reacted with
BP180-NC16A, 0.04 % (95 % CI: 0.00–0.09 %) with
BP230, 0.21 % (95 % CI: 0.11–0.32 %) with Dsg1 and
0.10 % (95 % CI: 0.03–0.17 %) with Dsg3 (Table 2). Al-
though recombinant antigen reactivity was observed in
indirect IF microscopy, visible esophagus tissue staining
was frequently absent. In detail, only 5 % of all BP180/
230-positive samples showed a basement membrane
pattern, whereas 55 % of all Dsg1/3-positive samples
showed a desmosomal pattern irrespective of the mea-
sured ELISA values. Overall, 0.31 % (CI: 0.18–0.44 %)
of healthy blood donors had autoantibodies against
pemphigus antigens, and 0.52 % (95 % CI: 0.36–0.69 %)
showed reactivity with BP180-NC16A, the relevant
pathogenic epitope of BP [23–25].
Validation of detected autoantibody prevalence
Next, positively rated samples (BP180-NC16A, BP230
and Dsg 1/3 reactivity) were validated by ELISA (Fig. 1,
Table 2). Overall, anti-BP180-NC16A-, anti-BP230-, anti-
Dsg1- and anti-Dsg3 IF-positive samples had significantly
higher ELISA values than IF-negative samples. Remarkably,
BP180-NC16A ELISA reactivity was detected in 35 of 37
indirect IF microscopy-positive samples, and 16 of those
were above the cut-off value for the diagnosis of BP (20
RU/ml). Regarding BP230 indirect IF microscopy-positive
samples, 2 of 3 had anti-BP230 antibodies detectable by
ELISA. In 7 of 15 Dsg1 indirect IF microscopy-positive
samples reactivity was also detected by ELISA, while 8
samples were negative. Of 7 Dsg3 indirect IF microscopy-
positive samples, 6 had autoantibodies that were detect-
able by ELISA.
BP180-NC16A autoantibodies from healthy blood donors
form immune complexes and dose-dependently activate
neutrophils
The binding of neutrophils to immune complexes (ICs)
leads to their activation, which can be analyzed by their
release of reactive oxygen species (ROS) [26]. Incubation
of polymorphonuclear leukocytes (PMN) from healthy
blood donors with IC of recombinant BP180-NC16A
and BP patient plasma leads to a significant ROS release
[21]. When recombinant BP180-NC16A was incubated
with plasma from healthy blood donors, ROS release
was identical to baseline (antigen only) when BP180-
NC16A-negative or -positive samples (below the diagnostic







Negative [n] Below diagnostic cut-off [n] Above diagnostic cut-off (≥20 RU/ml) [n]
Dsg1# 15 0.21 (0.11-0.32) 8 6 1
Dsg3# 7 0.10 (0.03-0.17) 1 6 0
BP180-NC16A§ 37 0.52 (0.36-0.69) 2 19 16
BP230# 3 0.04 (0.00-0.09) 1 2 0
*From a total of 7063 samples. Numbers in parentheses correspond to a 95 % confidence interval. This table contains double positives. **All IIF-positive samples
were included (15 for Dsg1, 7 for Dsg3, 37 for BP180-NC16A, 3 for BP230). #Transfected HEK cells expressing recombinant antigen. §Purified spotted protein.
Abbreviations used: IIFM, indirect immunofluorescence microscopy
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(above the diagnostic cut-off) plasma samples from healthy
blood donors were used, this led to an increase in ROS
release similar to the effect of samples from BP patients
(Fig. 2a). Overall, the concentration of anti-BP180-NC16A
IgG correlated with the ROS release from PMN (Fig. 2b),
indicating that anti-BP180-NC16A IgG from healthy blood
donors is able to activate PMN in vitro.Fig. 1 ELISA values of indirect IF microscopy-positive and indirect IF microsco
(green) and indirect IF-microscopy negative (red) samples according to the m
anti-Dsg3-positive samples have significantly higher ELISA values than antibod
correction. All indirect IF microscopy-positive samples [n: indirect IF microscop
[37] for BP180-NC16A, 3 [9] for BP230. *p < 0.05, ***p < 0.001 (comparing indir
Abbreviations: IIFM: indirect IF microscopyBP180-NC16A autoantibodies detected in healthy blood
donors are predominantly of the IgG3 subclass
In endemic pemphigus, a shift from IgG1 to IgG4 auto-
antibodies has been linked to pathogenesis [27]. To test
whether the IgG subclasses differ among anti-BP180-
NC16A IgG from healthy individuals, as opposed to BP
patients, a modified BP180-NC16A ELISA was performed.
As shown in Table 3, the frequencies of all IgG subclassespy-negative samples. Percentage of indirect IF microscopy (IIFM)-positive
easured ELISA values. Anti-BP180-NC16A-, anti-BP230-, anti-Dsg1-and
y-negative samples by the Wilcoxon rank-sum test with continuity
y-negative samples] were included: 15 [27] for Dsg1, 7 [13] for Dsg3, 37
ect IF microscopy-negative with indirect IF microscopy-positive samples).
Fig. 2 Anti-BP180-NC16A autoantibodies from healthy individuals induce ROS release from neutrophils. (a) ROS release of immune complex-activated
PMN in relation to cells incubated with antigen only. Owing to the non-parametric distribution, the data are presented as the median (line),
25/75-percentile (boxes), 5/95-percentiles (error bars) and outliers (dots). *p < 0.05 (ANOVA on ranks followed by Dunn’s method for multiple
comparisons versus control (NC16A-negative samples). (b) Concentrations of anti-BP180-NC16A IgG correlate with the amount of ROS release
from PMN (r = 0.786, p < 0.001, Pearson product-moment correlation)
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NC16A-IgG positive blood donors compared to BP pa-
tients. This was most pronounced for IgG2. Anti-BP180-
NC16A IgG3 was found most often in the BP180-NC16A
IgG-positive healthy blood donors (Table 3).
Epitopes targeted by BP180-NC16A autoantibodies
detected in healthy blood donors do not overlap with
those predominantly recognized by BP patients
As intramolecular epitope spreading towards certain epi-
topes of Dsg1 has been reported to lead to clinical dis-
ease manifestation in endemic pemphigus [28], we next
compared the fine epitope specificity of BP180-NC16A
IgG from healthy individuals and BP patients. The anti-
BP180-NC16A IgG reactivity in BP patients had been
shown to cluster at epitopes located within the BP180-
NC16A2-3 region [29, 30]. In our cohort of BP patients,
10/18 (56 %) samples reacted with this epitope, confirm-
ing these previous findings. Interestingly, BP180-NC16A-
positive samples from healthy blood donors rarely bound
to this epitope. In detail, only 2/10 samples below theTable 3 Subclasses of anti-BP180-NC16A IgG in healthy blood
donors and bullous pemphigoid patients
IgG1 IgG2 IgG3 IgG4
Healthy, < 20 RU/ml* 0/10 1/10 5/10 0/10
Healthy, ≥ 20 RU/ml* 2/10 1/10 4/10 1/10
BP patients 4/10 7/10 7/10 0/10
Healthy blood donors 0/10 0/10 0/10 0/10
*value of BP180-NC16A ELISAdiagnostic cut-off, and 1/10 samples above the diagnostic
cut-off, recognized this epitope (Fig. 3).
IgG from healthy individuals with antibody reactivity to
Dsg3 do not induce Dsg3 internalization in vitro
We also tested for potential pathogenicity of the detected
anti-Dsg3 IgG reactivity in the healthy blood donors.Fig. 3 Anti-BP180-NC16A autoantibodies from healthy individuals
bind to different epitopes within the NC16A domain. Samples from
the indicated groups were tested for their IgG reactivity against
NC16A2-3 (RSILPYGDSMDRIEKDRLQGMAPAAGADL). As reported
previously [29, 30], high reactivity with this epitope was observed
in BP patients. By contrast, only a minority of samples from healthy
individuals with IgG reactivity against NC16A showed reactivity
with this epitope. Abbreviations: NHS: normal human sera
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ization of Dsg3 when incubated with HaCaT cells, as
opposed to IgG from a pemphigus vulgaris patient (Fig. 4).
This lack of pathogenicity is most likely due to the low
anti-Dsg3 IgG concentrations in these samples.
Discussion
Our data document an overall low prevalence of pem-
phigus and bullous pemphigoid IgG autoantibodies in a
collection of 7063 blood donors. To date, this is the largest
population studied for pemphigus and pemphigoid auto-
antibodies. In line with BP being the most common AIBD
in central European countries, we found BP-associated
autoantibodies more frequently than pemphigus-associated
autoantibodies. Compared to the reported prevalence
of pemphigus (0.004 %) and pemphigoid (0.016 %) in
Denmark [31], the autoantibody prevalence reported
here is 25 or 37-fold higher. Hence, one may assume
that in BP and pemphigus, as reported for other auto-
immune diseases [17, 18], autoantibodies predate the
onset of clinical disease. Based on the prevalence of
pemphigus and pemphigoid antibodies in healthy individ-
uals and the prevalence of AIBD, every 25th individual
with autoantibodies against pemphigus antigens is likely
to develop pemphigus; similarly, every 37th healthy indi-
vidual with anti-BP180-NC16A IgG reactivity would be
expected to develop BP. This process would be initiated
by the break of tolerance and the generation of autoanti-
bodies to structural proteins of the skin. Subsequently, an
AIBD will become clinically manifest in only a minority of
affected autoantibody-positive healthy individuals. In the
future, additional biomarkers will hopefully allow cliniciansFig. 4 Anti-Dsg3 autoantibodies detected in healthy blood donors do not
IgG from healthy individuals (NH-IgG), IgG from a pemphigus vulgaris patie
donors (samples #1382, #3167 and #9607), as well as with a Dsg3-negative
concentration was 1 mg/ml (with the exception of the diluted PV-IgG sam
PV-IgG at 1:1 and 1:100 dilutions led to Dsg3 internalization. At low diluti
donors did not show any effects on Dsg3 internalizationto distinguish between “resistant” antibody-positive in-
dividuals and those who are prone to developing overt
clinical disease.
In contrast to the detection of other autoantibodies in
healthy individuals, e.g., ANA [17], the potential patho-
genic activity of anti-BP180-NC16A IgG and Dsg1/3 can
be tested [6]. As shown here, anti-BP180-NC16A IgG
from healthy blood donors induces neutrophil activation
in vitro. Because neutrophil activation is a key require-
ment for BP pathogenesis [32], the blister-inducing ability
of these autoantibodies can be assumed. Furthermore,
anti-BP180-NC16A IgG subclasses were identical between
healthy blood donors and BP patients (Table 3). Our result
that no IgG4 anti-BP180-NC16A antibodies were detected
in BP patients seemingly contradicts a previous report
[33], although it might be due to the small number of BP
serum samples included in our current study. In addition,
the fine mapping of the autoantibody response in our
samples revealed differences in the cohort of healthy
blood donors compared to BP patients (Fig. 3). This is
similar to observations made for endemic pemphigus with
autoantibodies directed against Dsg1. Epidemiologic stud-
ies demonstrated a shift from IgG1 to IgG4 autoantibodies
[34] and intramolecular epitope spreading towards certain
epitopes [28] upon development of skin blisters in en-
demic pemphigus foliaceus. The anti-Dsg3-positive sera
from our collection of healthy blood donors demonstrated
a lack of pathogenic potential of these autoantibodies,
which is most likely due to the low concentration of auto-
antibodies in the samples (Fig. 4).
Our results on the prevalence of autoantibodies to struc-
tural proteins of the skin also resolve the discrepancieslead to Dsg3 internalization in vitro. HaCaT cells were incubated with
nt (PV-IgG) or with Dsg3-positive plasma samples from healthy blood
sample (sample #4025). For all experimental conditions (n = 3), the IgG
ples). While NH-IgG and 4025 did not induce Dsg3 internalization,
ons, PV-IgG and all tested Dsg3-positive samples from healthy blood
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Dsg1 antibodies, the reported prevalences in healthy indi-
viduals ranged from 0 % to 0.7 %. A study by Ishii et al.
included 53 healthy control sera, and none reacted to
baculovirus-expressed Dsg1 in an ELISA [35]. In a study by
Schmidt et al., 401 healthy blood donors were included,
and circulating Dsg1 antibodies were detected using
ELISA with the Dsg1 ectodomain, expressed in a human
cell line, as a substrate. There, 3 of the 401 healthy con-
trols had ELISA values above the diagnostic cut-off for
pemphigus [20]. We showed here that 0.1 % of healthy in-
dividuals have detectable Dsg1 autoantibodies, which were
detected by indirect IF microscopy using Dsg1-expressing
cells as a substrate. Validation of the 15 indirect IF-
positive samples by ELISA showed reactivity in 7 of the
samples. However, with the exception of one sample, the
values were below the diagnostic cut-off value. Compared
with the study of Schmidt et al. we found far fewer Dsg1-
reactive samples. This may be explained by the fact that
Schmidt et al. defined Dsg1 positivity sorely by ELISA. In
contrast, in our study, only those sera were considered
positive that reacted with Dsg1 by both indirect IF mi-
croscopy and ELISA. Similar considerations also hold
true for the other autoantigens in AIBD tested within
our study (Table 1).
Conclusion
In summary, we here document the prevalence of pem-
phigus and pemphigoid autoantibodies in a large cohort
of healthy blood donors. The comparison of the auto-
antibody prevalence and the prevalence of the corre-
sponding AIBD may suggest that these diseases develop
over a prolonged period of time.
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